25
Sep

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that’s the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.

…read more

Source: Valeant talks up the billion-dollar potential of its Phase III eye drug

    

0 No comments